Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 29, 2012

Study Completion Date

October 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)

"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."

Trial Locations (1)

10065

Weill Medcial College of Cornell University, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT00195039 - Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter